The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE).
Chiara Lazzari
No relevant relationships to disclose
Silvia Novello
No relevant relationships to disclose
Sandro Barni
No relevant relationships to disclose
Michele Aieta
No relevant relationships to disclose
Filippo De Marinis
No relevant relationships to disclose
Tommaso De Pas
No relevant relationships to disclose
Francesco Grossi
No relevant relationships to disclose
Manlio Mencoboni
No relevant relationships to disclose
Alessandra Bearz
No relevant relationships to disclose
Irene Floriani
No relevant relationships to disclose
Valter Torri
No relevant relationships to disclose
Alessandra Bulotta
No relevant relationships to disclose
Julia Grigorieva
Employment or Leadership Position - Biodesix
Stock Ownership - Biodesix
Research Funding - Biodesix
Joanna Roder
Employment or Leadership Position - Biodesix (B)
Stock Ownership - Biodesix (B)
Claudio Doglioni
No relevant relationships to disclose
Heinrich Roder
Employment or Leadership Position - Biodesix (B)
Stock Ownership - Biodesix (B)
Luisella Righi
No relevant relationships to disclose
Silvia Foti
No relevant relationships to disclose
Angela Bachi
No relevant relationships to disclose
Vanesa Gregorc
No relevant relationships to disclose